-
Acceleron Stops Clinical Development of ACE-083 for FSHD
Acceleron Pharma will stop clinical development of its ACE-083 candidate for facioscapulohumeral muscular dystrophy due to lack of efficacy, officials said. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.